Inari Medical, Inc. (NARI) Tops Q4 EPS by 12c, Revenues Beat; Offers 1Q & FY21 Revenues Guidance Above Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. NVDA
7. USO
8. LMT
9. AMZN
10. META

Go back to Inari Medical, Inc. (NARI) Tops Q4 EPS by 12c, Revenues Beat; Offers 1Q & FY21 Revenues Guidance Above Consensus

Inari Medical Reports Fourth Quarter and Full Year 2020 Financial Results

March 9, 2021 4:01 PM EST

IRVINE, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (Inari) a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today reported financial results for its fourth quarter and full year ended December 31, 2020.

Fourth Quarter Revenue and Business Highlights:

Treated a record 4,600 patients, up 24% sequentially, driving revenue of $48.6 million, which was up 26% sequentially and 144% over the prior year period.Introduction of multiple new products... More